We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Genuit Group Plc | LSE:GEN | London | Ordinary Share | GB00BKRC5K31 | ORD GBP0.001 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-6.00 | -1.36% | 434.00 | 434.00 | 436.00 | 443.00 | 434.00 | 442.50 | 189,621 | 16:35:19 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Plastics Pipe | 586.5M | 38.5M | 0.1551 | 28.11 | 1.08B |
TIDMGEN
Media Release
Copenhagen, Denmark, November 3, 2022
-- Nineteen abstracts accepted, including multiple presentations on the safety and efficacy of investigational epcoritamab (DuoBody(R)-CD3xCD20) in a variety of treatment settings and hematologic malignancies -- Four oral presentations highlighting data evaluating epcoritamab for the treatment of relapsed/refractory (R/R) large B-cell lymphoma (LBCL), R/R follicular lymphoma (FL), previously untreated FL, and Richter's syndrome -- New data evaluating investigational medicines in Genmab's early portfolio of cancer immunotherapies will also be presented -- Genmab to host 2022 R&D Update and ASH Data Review meeting December 12
https://www.globenewswire.com/Tracker?data=lUGs-QmMVmjTq3ELJMrhrqNBoY5CIrPSzsZ1Mi1ZBKkf6dYcXHivF3_L5pnvi4ogT4o-LGUAla4shx1a20wfhA== Genmab A/S (Nasdaq: GMAB) announced today that 19 abstracts evaluating various investigational medicines in its pipeline have been accepted for presentation at the 64(th) Annual Meeting and Exposition of the American Society of Hematology (ASH), being held at the Ernest N. Morial Convention Center in New Orleans, Louisiana, and virtually, December 10-13. The presentations will include four oral and six poster presentations highlighting data from several clinical trials evaluating the safety and efficacy of epcoritamab (DuoBody(R) -CD3xCD20), an investigational subcutaneous IgG1-bispecific antibody created using Genmab's proprietary DuoBody technology, alone or in combination for the treatment of patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL), R/R follicular lymphoma (FL), previously untreated FL and Richter's syndrome.
Additionally, abstracts evaluating two investigational medicines in Genmab's early pipeline have been accepted for presentation, including the first-in-human data from the phase 1/2 trial evaluating GEN3014 (HexaBody(R) -CD38), an investigational novel human CD38 monoclonal antibody, in patients with R/R multiple myeloma (MM). In addition, preclinical data from a novel drug candidate GEN3017 (DuoBody(R) -CD3xCD30) will also be presented.
All abstracts accepted for presentation have been published on the ASH https://www.globenewswire.com/Tracker?data=fX18EJ7pQ7uUp2YKINsqZWhGFXLA6LXrll8mBtGVZNTIgV6jnOpB0E3BSxqORnb4Yuy3sCcqfGktMgjt1J3XXKZ_vyuzG6D2xLO8GUKOCug= website https://www.globenewswire.com/Tracker?data=VSUdnv4Cp3T_14QR2YAv9JevausivTrZVLEGEPRLe4NZLids2kUztXkRkkbxd4gK3c7tOw5z2PjPXJf_0bV-GsqDzkzJ3tZSgX1nxdGfe6eMgqO4hVHKjzwzW4jJ74yq .
Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies' oncology collaboration. The companies are committed to evaluating epcoritamab as a monotherapy, and in combination, across lines of therapy in a range of B-cell malignancies, including an ongoing phase 3, open-label, randomized clinical trial evaluating epcoritamab as a monotherapy in patients with relapsed/refractory LBCL, including DLBCL (NCT: 04628494) and a phase 3, open-label randomized clinical trial evaluating epcoritamab in combination in patients with relapsed/refractory follicular lymphoma (FL) (NCT: 05409066).
"As part of our commitment to the blood cancer community, we continue to advance our research and innovative technologies in an effort to develop differentiated therapies with the goal of transforming the future of treatment for patients," said Dr. Judith Klimovsky, Executive Vice President and Chief Development Officer of Genmab. "The robust data being presented at this year's American Society of Hematology meeting are encouraging and support the potential of epcoritamab to become a core therapy for B-cell malignancies."
2022 R&D Update and ASH Data Review
On Monday, December 12, at 8:00 PM EST (7:00 PM CST / 1:00 AM GMT), Genmab will host its 2022 R&D Update and ASH Data Review. The event will be conducted and webcast live. Details, including the webcast link and registration can be found here https://www.globenewswire.com/Tracker?data=xK0r4QlpcfwYqNpGTZqQkLAgnixqjEE2w6Bpe0aLVbClVWv72BU3dw52myFHbsZikXPCo5kQRwtcsbTHrjbwQLlrGAmZHdthg4XSruyEz2O-yCfJjPHN8PEIfddfymb6tvY2ICbdnvmPLka2r3RrMN9lBuVKNKGaxODRwQ8j-cE= . This meeting is not an official program of the ASH Annual Meeting.
Abstracts accepted at ASH:
Epcoritamab (DuoBody(R)-CD3xCD20)
Abstract Abstract Title Type of Date/Time of Number Presentation Presentation -------- ----------------------------------------------- ------------- -------------------- 348 Subcutaneous Epcoritamab in Patients Oral Saturday, December with Richter's Syndrome: Early Results 10, 4:00 PM - 5:30 from Phase 1b/2 Trial (EPCORE CLL-1). PM Kater et. al. -------- ----------------------------------------------- ------------- -------------------- 443 Subcutaneous Epcoritamab + R-DHAX/C Oral Sunday, December in Patients with Relapsed or Refractory 11, 9:30 AM - 11:00 Diffuse Large B-Cell Lymphoma Eligible AM for Autologous Stem Cell Transplant: Updated Phase 1/2 Results. Abrisqueta et. al. -------- ----------------------------------------------- ------------- -------------------- 609 Subcutaneous Epcoritamab with Rituximab Oral Sunday, December + Lenalidomide in Patients with Relapsed 11, 4:30 PM - 6:00 or Refractory Follicular Lymphoma: PM Phase 1/2 Trial Update. Falchi et. al. -------- ----------------------------------------------- ------------- -------------------- 611 Subcutaneous Epcoritamab in Combination Oral Sunday, December with Rituximab + Lenalidomide (R2) 11, 4:30 PM - 6:00 for First-Line Treatment of Follicular PM Lymphoma: Initial Results from Phase 1/2 Trial. Falchi et. al. -------- ----------------------------------------------- ------------- -------------------- 4251 Epcoritamab Monotherapy Provides Deep Poster Monday, December and Durable Responses Including Minimal 12, 6:00 PM - 8:00 Residual Disease (MRD) Negativity: PM Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL). Phillips et. al. -------- ----------------------------------------------- ------------- -------------------- 3580 Improvements in Lymphoma Symptoms and Poster Sunday, December Health-related Quality of Life in Patients 11, 6:00 PM - 8:00 with Relapsed or Refractory Large B-cell PM Lymphoma Treated with Epcoritamab. Phillips et. al. -------- ----------------------------------------------- ------------- -------------------- 4912 Indirect Comparison of the Efficacy Poster Monday, December of Subcutaneous Epcoritamab Dose Expansion 12, 6:00 PM - 8:00 (EPCORE NHL-1 Trial) in Patients With PM Relapsed or Refractory Large B-cell Lymphoma. Salles et. al. -------- ----------------------------------------------- ------------- -------------------- 2874 Deep peripheral T cell subset immune-profiling Poster Sunday, December in relapse/refractory non-Hodgkins 11, 6:00 PM - 8:00 lymphoma (NHL): Evaluation of baseline PM samples from the Epcoritamab 3013-01 trial. Blum et. al. -------- ----------------------------------------------- ------------- -------------------- 2859 Transcriptomic Comparison of Non-Hodgkin Poster Sunday, December Lymphomas in Relapsed/Refractory versus 11, 6:00 PM - 8:00 Newly Diagnosed Patients with Single PM Slides. Jabado et. al. -------- ----------------------------------------------- ------------- -------------------- 1663 Phase 1b Trial of Subcutaneous Epcoritamab Poster Saturday, December Among Pediatric Patients With Relapsed 10, 5:30 PM - 7:30 or Refractory Aggressive Mature B-Cell PM Neoplasms. Cairo et. al. -------- ----------------------------------------------- ------------- -------------------- 4182 Evaluation of Epcoritamab and Rituximab Poster Monday, December Combination in Preclinical Models of 12, 6:00 PM - 8:00 B-cell non-Hodgkin's Lymphoma (NHL). PM Epling-Burnette et. al. -------- ----------------------------------------------- ------------- -------------------- 4206 Phase 3 Trial of Subcutaneous Epcoritamab Poster Monday, December in Combination With Rituximab and Lenalidomide 12, 6:00 PM - 8:00 (R2) vs R2 Without Epcoritamab Among PM Patients With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1). Falchi et. al. -------- ----------------------------------------------- ------------- -------------------- 4271 Phase 2 Trial to Evaluate Safety of Poster Monday, December Subcutaneous Epcoritamab Monotherapy 12, 6:00 PM - 8:00
in the Outpatient Setting Among Patients PM With Relapsed or Refractory Diffuse Grade 1--3a Large B-Cell and Follicular Lymphoma. Sharman et. al. -------- ----------------------------------------------- ------------- -------------------- 5524 Assessing Safety, Tolerability, and Publication NA Efficacy of Subcutaneous Epcoritamab in Novel Combinations with Anti-Neoplastic Agents in Patients with Non-Hodgkin Lymphoma in a Phase 1b/2, Open-Label Study. Sehn et. al. -------- ----------------------------------------------- ------------- --------------------
GEN3014 (HexaBody(R) -CD38)
Abstract Abstract Title Type of Date/Time of Number Presentation Presentation -------- ------------------------------------------ ------------ ----------------- 3254 Preliminary Dose-Escalation Results Poster Sunday, December From a First-in-Human Phase 1/2 Study 11, 6:00-8:00 PM of GEN3014 (HexaBody(R)-CD38) in Patients (pts) With Relapsed or Refractory (R/R) Multiple Myeloma (MM). Spencer et. al. -------- ------------------------------------------ ------------ -----------------
GEN3017 (DuoBody(R) -CD3xCD30)
Abstract Abstract Title Type of Date/Time of Number Presentation Presentation -------- -------------------------------------------- ------------ ------------------- 1366 DuoBody(R)-CD3xCD30 shows potent preclinical Poster Sunday, December anti-tumor activity in vitro in CD30+ 11, 6:00 PM - 8:00 hematologic malignancies. Oostindie PM et. al. -------- -------------------------------------------- ------------ -------------------
Real-World Evidence
Abstract Abstract Title Type of Date/Time of Number Presentation Presentation -------- -------------------------------------------- ------------ ------------------- Real-World Outcomes in Patients with Poster Sunday, December 2978 Relapsed or Refractory Diffuse Large 11, 6:00 PM - 8:00 B-cell Lymphoma Treated with Standard PM of Care: a COTA Database Analysis. Ip et. al. -------- -------------------------------------------- ------------ ------------------- 2296 Treatment Patterns and Outcomes in Poster Saturday, December Patients With Follicular Lymphoma 10, 5:30 PM - 7:30 Receiving at Least 3 Lines of Therapy: PM a Real-World Evaluation in the United States. Phillips et. al. -------- -------------------------------------------- ------------ ------------------- 2215 Health Care Resource Utilization and Poster Saturday, December Costs of CAR T Therapy in Patients 10, 5:30 PM - 7:30 With Large B-Cell Lymphoma: A Retrospective PM US Claims Database Analysis. Davies et. al. -------- -------------------------------------------- ------------ -------------------
About Epcoritamab
Epcoritamab is an investigational IgG1-bispecific antibody created using Genmab's proprietary DuoBody technology. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response towards target cell types. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B-cells and induces T cell mediated killing of CD20+ cells.(i) CD20 is expressed on B-cells and a clinically validated therapeutic target in many B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and chronic lymphocytic leukemia.(ii) (,) (iii)
About Genmab
Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. For more than 20 years, Genmab's vision to transform cancer treatment has driven its passionate, innovative and collaborative teams to invent next-generation antibody technology platforms and leverage translational research and data sciences, fueling multiple differentiated cancer treatments that make an impact on people's lives. To develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab's proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.
Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com https://www.globenewswire.com/Tracker?data=lUGs-QmMVmjTq3ELJMrhrna90AytnvO5KeOWs7AHTRxmCzFRS-_IOtW2ZhsMhDQ60r7byuPLPO4oHw50bxo2KZ_7O0kvjzeZaswLD0TWMp15eEczMqb4B6hHOJKyX5AWEmzPajcy9kFKoN8daFXzbA== and follow us on Twitter.com/Genmab https://www.globenewswire.com/Tracker?data=F-EX5ih_eCYUbykGJO_iB6kX0yQGxKYHajsg6TlcqWHSeLk474GyenPPnPp4b2n0p9GrzDOu2iP93de3ZmG3VgNfyDNnOy4-GGFtFqXYtrQ= .
Contact:
David Freundel, Director, Product Communications
T: +1 609 613 0504; E: dafr@genmab.com https://www.globenewswire.com/Tracker?data=uK9hV5RKuF9T3Ge0wp1K7p1zEw7i80YEiJTPqG1mpnV-6vWcW3fN9_h95L8_I3nBwzSYlVMxtBrWf-z5M2KY9A==
For Investor Relations:
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com https://www.globenewswire.com/Tracker?data=Ox9PJoeFvpA1mO4hpLOM3iYAxWdSACT_jO1yjPU3TJrrprJ3IPHozg7WUgsBGb3fDFQSs5fnt0AFDYGgUTUqXg==
This Company Announcement contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on https://www.globenewswire.com/Tracker?data=aog4py-hyV5ryLaznm2gKq0tptOa8wy7QaF-0nFG66KSeCnK1cwfnXQVJsHRMZhXMSvdYL_AZdqE_TTlKwFB7A== www.genmab.com and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at https://www.globenewswire.com/Tracker?data=aog4py-hyV5ryLaznm2gKh1osDH_Qr4ZnE6_3hvj7AXwVoYzRkmrlP0Z6_RD2yMrrkBZ6zXQ6p-k8wJEUBuJwqtrGtIFc1_7Ru4hZChBweY= www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab(R) ; the Y-shaped Genmab logo(R) ; Genmab in combination with the Y-shaped Genmab logo(R) ; HuMax(R) ; DuoBody(R) ; DuoBody in combination with the DuoBody logo(R) ; HexaBody(R) ; HexaBody in combination with the HexaBody logo(R) ; DuoHexaBody(R) ; HexElect(R) ; and UniBody(R) .
(i) Engelberts et al. "DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing." EBioMedicine. 2020;52:102625. DOI: 10.1016/j.ebiom.2019.102625
(ii) Rafiq, Butchar, Cheney, et al. "Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage Properties." J. Immunol. 2013;190(6):2702-2711. DOI: 10.4049/jimmunol.1202588
(iii) Singh, Gupta, Almasan. "Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response." J Cancer Sci Ther. 2015;7(11):347-358. DOI: 10.4172/1948-5956.1000373
Media Release no. 15
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark
Attachment
-- Genmab 2022 ASH Curtain Raiser_FINAL https://ml-eu.globenewswire.com/Resource/Download/39fb4136-efbb-4068-bfce-f3188c49c224
(END) Dow Jones Newswires
November 03, 2022 09:01 ET (13:01 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Genuit Chart |
1 Month Genuit Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions